1. Home
  2. FULC vs ONDS Comparison

FULC vs ONDS Comparison

Compare FULC & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FULC
  • ONDS
  • Stock Information
  • Founded
  • FULC 2015
  • ONDS 2014
  • Country
  • FULC United States
  • ONDS United States
  • Employees
  • FULC N/A
  • ONDS N/A
  • Industry
  • FULC Biotechnology: Pharmaceutical Preparations
  • ONDS Telecommunications Equipment
  • Sector
  • FULC Health Care
  • ONDS Telecommunications
  • Exchange
  • FULC Nasdaq
  • ONDS Nasdaq
  • Market Cap
  • FULC 221.5M
  • ONDS 218.8M
  • IPO Year
  • FULC 2019
  • ONDS N/A
  • Fundamental
  • Price
  • FULC $3.96
  • ONDS $2.07
  • Analyst Decision
  • FULC Hold
  • ONDS Buy
  • Analyst Count
  • FULC 10
  • ONDS 1
  • Target Price
  • FULC $7.44
  • ONDS $4.00
  • AVG Volume (30 Days)
  • FULC 1.0M
  • ONDS 11.0M
  • Earning Date
  • FULC 02-25-2025
  • ONDS 11-12-2024
  • Dividend Yield
  • FULC N/A
  • ONDS N/A
  • EPS Growth
  • FULC N/A
  • ONDS N/A
  • EPS
  • FULC N/A
  • ONDS N/A
  • Revenue
  • FULC $80,871,000.00
  • ONDS $8,024,937.00
  • Revenue This Year
  • FULC $2,821.96
  • ONDS N/A
  • Revenue Next Year
  • FULC N/A
  • ONDS $279.95
  • P/E Ratio
  • FULC N/A
  • ONDS N/A
  • Revenue Growth
  • FULC 2987.86
  • ONDS N/A
  • 52 Week Low
  • FULC $2.86
  • ONDS $0.54
  • 52 Week High
  • FULC $13.70
  • ONDS $3.40
  • Technical
  • Relative Strength Index (RSI)
  • FULC 41.64
  • ONDS 52.50
  • Support Level
  • FULC $3.93
  • ONDS $1.82
  • Resistance Level
  • FULC $5.17
  • ONDS $2.27
  • Average True Range (ATR)
  • FULC 0.30
  • ONDS 0.42
  • MACD
  • FULC -0.13
  • ONDS -0.10
  • Stochastic Oscillator
  • FULC 3.97
  • ONDS 15.82

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

About ONDS Ondas Holdings Inc.

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

Share on Social Networks: